This article explains how many hospitals in the UK are using DILAPAN-S for induction of labour and why DILAPAN-S is becoming a preferred option.

Recent regulatory scrutiny in Germany has cast a spotlight on misoprostol (Angusta) and its role in labour induction, raising significant safety concerns. As this conversation unfolds across Europe, healthcare professionals are re-evaluating their induction protocols and looking to non-pharmacological methods like DILAPAN-S as a safer alternative.